Table 4.
Comparison of cellular and humoral responses between SARS-CoV-2-naïve and SARS-CoV-2-infected patients with full vaccination.
| Vaccinated with no history of COVID-19 |
Vaccinated with history of COVID-19 |
p-value | |||
|---|---|---|---|---|---|
| Median [IQR] | n | Median [IQR] | n | ||
| SARS-CoV-2 anti-spike IgG antibodies at T1, AU/mL (Abbott) | 3180 [1008–6029] | 43 | 40,000 [17,230–40,000] | 6 | <0.001 |
| SARS-CoV-2 anti-spike IgG antibodies at T2, AU/mL (Abbott) | 1894 [583–5268] | 53 | 14,653 [10,584–40,000] | 5 | <0.001 |
| SARS-CoV-2 anti-spike IgG antibodies at T1, % (GenID) | 76 [67.2–88.2] | 44 | 91.5 [82.7–95.2] | 6 | 0.042 |
| SARS-CoV-2 anti-spike IgG antibodies at T2, % (GenID) | 83 [54–91] | 53 | 92 [68.5–97] | 5 | 0.15 |
| IL-2 at T1, SI | 2 [1.5–3.5] | 39 | 17.7 [3.1–21.4] | 6 | 0.004 |
| IL-2 at T2, SI | 1.67 [1–4.4] | 37 | 35.3 [1.5–105] | 5 | 0.07 |
| IFN-γ at T1, SI | 3 [1–4] | 42 | 35 [20–195] | 6 | <0.001 |
| IFN-γ at T2, SI | 3 [1–6] | 47 | 110 [22–186] | 5 | <0.001 |
Bolded p-values denote statistical significance at the p < 0.05 level.
COVID-19, coronavirus disease 2019; IFN-γ, interferon-γ; IL-2, interleukin-2; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus type-2; T1, timepoint 1; T2, timepoint 2.